Cargando…
A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients
Recent studies demonstrate robust molecular cross talk and signaling between hydrogen sulfide (H(2)S) and nitric oxide (NO). Heart failure (HF) patients are deficient in both H(2)S and NO, two molecules that are critical for cardiovascular homeostasis. A phase I clinical trial of a novel H(2)S prodr...
Autores principales: | Polhemus, David J., Li, Zhen, Pattillo, Christopher B., Gojon, Gabriel, Giordano, Tony, Krum, Henry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034803/ https://www.ncbi.nlm.nih.gov/pubmed/25930144 http://dx.doi.org/10.1111/1755-5922.12128 |
Ejemplares similares
-
SG1002 and Catenated Divalent Organic Sulfur Compounds as Promising Hydrogen Sulfide Prodrugs
por: Gojon, Gabriel, et al.
Publicado: (2020) -
Hydrogen sulfide prodrugs—a review
por: Zheng, Yueqin, et al.
Publicado: (2015) -
Anti‐inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H(2)S donors in COVID‐19 therapy
por: Citi, Valentina, et al.
Publicado: (2020) -
Zofenopril Protects Against Myocardial Ischemia–Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability
por: Donnarumma, Erminia, et al.
Publicado: (2016) -
Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability?
por: Whiteman, Matthew, et al.
Publicado: (2009)